Evidence map›Paper›PMID 23582329›Full record

ArticleCell2013

The fractalkine/CX3CR1 system regulates β cell function and insulin secretion.

Yun Sok Lee, Hidetaka Morinaga, Jane J Kim, William Lagakos, Susan Taylor, Malik Keshwani, Guy Perkins, Hui Dong, Ayse G Kayali, Ian R Sweet and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed, 1 pooled it
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.

  1. Pooled it
  2. Monocyte Migration Emerges from a Divergent Chemokine Signaling Network.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Chemokine CX3CL1 (Fractalkine) Signaling and Diabetic Encephalopathy.International journal of molecular sciences · 2024
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Exercise and inactivity as modifiers of β cell function and type 2 diabetes risk.Journal of applied physiology (Bethesda, Md. : 1985) · 2023
    Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yun Sok LeeDepartment of Medicine, Division of Endocrinology and Metabolism, University of California, San Diego, La Jolla, CA 92093, USA.
Hidetaka Morinaga
Jane J Kim
William Lagakos
Susan Taylor
Malik Keshwani
Guy Perkins
Hui Dong
Ayse G Kayali
Ian R Sweet
Jerrold Olefsky
University of California, San Diego · USUniversity of Washington · US

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Sakeneh Zraika · 1986 to 2026
$41.4M
Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PETER J TONTONOZ · 2003 to 2026
$40.4M
The Interaction of Neuroendocrine Repro. Function and Metabolic SignalingU54HD012303 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MELLON, PAMELA L · 1999 to 2013
$18.0M
Transcriptional Genomics CoreP01DK074868 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GLASS, CHRISTOPHER K · 2007 to 2016
$16.6M
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEMR37DK033651 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI OLEFSKY, JERROLD MICHAEL · 2000 to 2010
$6.1M
TRAINING PROGRAM IN DIABETES RESEARCHT32DK007494 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SALTIEL, ALAN R. · 1986 to 2021
$4.7M
INSULIN RECEPTORS AND THE GLUCOSE TRANSPORT SYSTEMR01DK033651 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI OLEFSKY, JERROLD MICHAEL · 1986 to 2013
$2.2M
Effects of Fractalkine on Beta Cell FunctionR01DK101395 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI OLEFSKY, JERROLD MICHAEL · 2014 to 2017
$1.6M
NICHD NIH HHS U54 HD012303NICHD NIH HHS U54-HD-012303-25NIDDK NIH HHS DK-033651NIDDK NIH HHS DK-063491NIDDK NIH HHS DK-074868NIDDK NIH HHS P01 DK074868NIDDK NIH HHS P30 DK017047NIDDK NIH HHS P30 DK063491NIDDK NIH HHS R01 DK033651NIDDK NIH HHS R01 DK101395NIDDK NIH HHS R37 DK033651NIDDK NIH HHS T32 DK007494NIDDK NIH HHS T32-DK-007494
6 · The paper itself

Abstract

Here, we demonstrate that the fractalkine (FKN)/CX3CR1 system represents a regulatory mechanism for pancreatic islet β cell function and insulin secretion. CX3CR1 knockout (KO) mice exhibited a marked defect in glucose and GLP1-stimulated insulin secretion, and this defect was also observed in vitro in isolated islets from CX3CR1 KO mice. In vivo administration of FKN improved glucose tolerance with an increase in insulin secretion. In vitro treatment of islets with FKN increased intracellular Ca(2+) and potentiated insulin secretion in both mouse and human islets. The KO islets exhibited reduced expression of a set of genes necessary for the fully functional, differentiated β cell state, whereas treatment of wild-type (WT) islets with FKN led to increased expression of these genes. Lastly, expression of FKN in islets was decreased by aging and high-fat diet/obesity, suggesting that decreased FKN/CX3CR1 signaling could be a mechanism underlying β cell dysfunction in type 2 diabetes.

Indexed as

Signal TransductionAdultAgingAnimalsCadaverChemokine CX3CL1CX3C Chemokine Receptor 1Diet, High-FatGene ExpressionGlucoseHumansHyperglycemiaInsulinInsulin-Secreting CellsInsulin SecretionIslets of LangerhansChemokine CX3CL1CX3C Chemokine Receptor 1CX3CR1 protein, humanCx3cr1 protein, mouseGlucoseInsulinReceptors, Chemokine

Identifiers

PMID23582329
PMCPMC3717389
OpenAlexW1965673611

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.